Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Order Full text via Infotrieve
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belliveau, P.
Right arrow Articles by Maday, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belliveau, P.
Right arrow Articles by Maday, C.
American Journal of Health-System Pharmacy, Vol 53, Issue 13, 1570-1575
Copyright © 1996 by American Society of Health-System Pharmacists


Articles

Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium

PP Belliveau, AL Rothman, and CE Maday


The implementation, monitoring, and impact of a program to restrict vancomycin use are described. A vancomycin restriction program was implemented in February 1995 at an acute care teaching hospital after guidelines for vancomycin use were established by a multidisciplinary group. Pharmacists reviewed each vancomycin order, suggested alternative treatments when vancomycin use did not comply with the guidelines, and set duration limits for all orders. Orders requiring greater clinical experience for review were referred to a pharmacist or a physician in the division of infectious diseases. The program was monitored by an infectious diseases pharmacist. Data collected after the program was established showed that the volume of vancomycin use decreased substantially. Problems in enforcing the restriction program included administration of vancomycin for surgical prophylaxis before the order reached the pharmacy, continuing use of vancomycin for initial empirical treatment of febrile neutropenic and immunocompromised patients, inadequate tracking of the evaluations, and deficiencies in the evaluations related to a need for continuing education of the pharmacists about the program. Use of vancomycin decreased after a pharmacy-enforced restriction program was implemented.
 



This article has been cited by other articles:


Home page
J CARDIOVASC PHARMACOL THERHome page
M.-R. Movahed, B. Kasravi, and C. S. Bryan
Prophylactic Use of Vancomycin in Adult Cardiology and Cardiac Surgery
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 13 - 20.
[Abstract] [PDF]


Home page
J Antimicrob ChemotherHome page
C. Ramsay, E. Brown, G. Hartman, P. Davey, and on behalf of the joint BSAC/HIS Working Party on O
Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing
J. Antimicrob. Chemother., November 1, 2003; 52(5): 764 - 771.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Society of Health-System Pharmacists.